NEW YORK (GenomeWeb News) – Life Technologies has struck a collaborative partnership with the Structural Genomics Consortium to develop and release 200 highly specific epigenetic recombinant antibodies, the company said today.

The partners have now released 58 of these antibodies, a move that SGC Director and CEO Aled Edwards said in a statement marks "the first step toward developing the defacto standard set of quality epigenetics antibodies that researchers can use for generations to come."

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.